The Evolution of TAVR and the Quest for Versatility
Since the inception of transcatheter aortic valve replacement (TAVR), the landscape has been dominated by a few established platforms, primarily the balloon-expandable SAPIEN series and the self-expanding Evolut series. While these devices have revolutionized the treatment of symptomatic severe aortic stenosis, particularly in high-risk and elderly populations, the search for next-generation valves that offer greater sizing precision and comparable long-term efficacy continues. The LANDMARK trial represents a pivotal moment in this evolution, evaluating the Myval balloon-expandable transcatheter heart valve (THV) series against these established contemporary standards.
